

Laribacter hongkongensis: The First Identification at Rajavithi Hospital

Thongkoom P, MSc¹, Intalaphaporn P, MD²

¹ Microbiology Section, Department of Medical Technology, Rajavithi Hospital, Bangkok, Thailand

² Division of Infectious Diseases, Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand

Background: This is the first report of *Laribacter hongkongensis* that was isolated from the Rajavithi microbiology section at Rajavithi Hospital. *L. hongkongensis* is an emerging pathogen that causes bacteremia, community-acquired gastroenteritis and traveler's diarrhea. *L. hongkongensis* is a gram-negative with seagull- or S-shaped rod, facultative anaerobic, non-fermentative bacillus. The distribution of *L. hongkongensis* had been described worldwide, but because of limitation of methods for accurate identification of *L. hongkongensis*, data reports about of them were few.

Objective: To present the phenotypic characteristics and antimicrobial susceptibilities of *L. hongkongensis* (LHRJ) strain.

Materials and Methods: *L. hongkongensis* had isolated from hemoculture of a Rajavithi's patient. Using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) method for *L. hongkongensis* identification, phenotypic characterization were described. The antimicrobial susceptibility of *L. hongkongensis* was determined.

Results: *L. hongkongensis*, Rajavithi (LHRJ) strain is motile, positive to urease, arginine dihydrolase, catalase, oxidase tests and reduce nitrate. The LHRJ strain was susceptible to most of antimicrobial agents, except ampicillin, cefotaxime, ceftriaxone, and ceftazidime.

Conclusion: *L. hongkongensis* is difficult to accurate identification by conventional biochemical method. Using the MALDI-TOF MS, which these bacteria database, has been identified accurately. However, some important characteristics of this bacterium have been reminded to microbiologists. The microbiology laboratory must be aware of accurate identification and antimicrobial susceptibility in the testing of *L. hongkongensis* isolates, especially in immuno-compromised patients, for appropriate treatment.

Keywords: *Laribacter hongkongensis*, MALDI-TOF MS, Antimicrobial susceptibility

J Med Assoc Thai 2019;102(Suppl.4):132-6

Website: <http://www.jmatonline.com>

Laribacter hongkongensis is a gram-negative, facultative anaerobic, non-sporulating, seagull- or S-shaped bacillus and belongs to the family *Neisseriaceae* of the beta subclass of *Proteobacteria*⁽¹⁾. *L. hongkongensis* is an emerging pathogen bacteremia, community-acquired gastroenteritis and traveler's diarrhea⁽¹⁻⁷⁾. *L. hongkongensis* was first reported in Hong Kong isolated from blood and empyema pus of a 54-year-old Chinese man with alcoholic liver cirrhosis in 2001⁽¹⁾. *L. hongkongensis* infections are global important pathogens, these isolations have been reported from a variety geographic areas such as Asia, Europe, Africa and Central America⁽⁶⁻⁸⁾. The most common isolates of *L. hongkongensis* are found in Asia⁽¹⁻¹⁰⁾.

The reservoirs of *L. hongkongensis* are freshwater fish and Chinese tiger⁽²⁻⁵⁾. The clinical syndrome of *L.*

hongkongensis infections associated with gastroenteritis is similar to those of *Salmonella* or *Campylobacter*-infected patients⁽²⁾. Most patients have watery or bloody diarrhea and some of them may have systemic symptoms^(6,7). Fortunately, there are no reported deaths from *L. hongkongensis* infections.

Most *L. hongkongensis* strains have been found to be resist to most beta-lactams including ampicillin and cephalosporins and tetracycline, due to a chromosomal class C beta-lactamase and plasmid-encoded *tetA* genes^(9,10). All *L. hongkongensis* isolates were still susceptible to carbapenems^(1,4,8,11,17). However, there were some different antibiotic susceptibility profiles^(1,4,8,11,17).

The prevalence, epidemiology and clinical pathology of *L. hongkongensis* infections have been unclear, because of limitations of *L. hongkongensis* identification in a microbiological laboratory. Although, *L. hongkongensis* isolate is a non-fastidious organism, easy to grow on blood agar and MacConkey agar in ambient temperature, it cannot correctly provide identification by conventional biochemical methods and automatic machines that do not show a database for *L. hongkongensis* strains^(1,8). Identification of

Correspondence to:

Thongkoom P.

Microbiology Section, Department of Medical Technology, Rajavithi Hospital, 2 Phayathai Road, Ratchathewi, Bangkok 10400, Thailand.

Phone: +66-2-3548108

E-mail: thongkoomp@gmail.com

How to cite this article: Thongkoom P, Intalaphaporn P. *Laribacter hongkongensis*: the First Identification at Rajavithi Hospital J Med Assoc Thai 2019; 102(Suppl.4):132-6.

L. hongkongensis is by using molecular, sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) methods, which are more accurate methods^(1,8,12-14).

The aim of this report is to present the phenotypic characteristics and antimicrobial susceptibilities of the *L. hongkongensis* (LHRJ) strain.

Materials and Methods

Bacterial strain

At Rajavithi microbiology laboratory, the BD BACTEC™ FX (Becton Dickinson and Company, Sparks, MD) for hemoculture was used. On July 3, 2017, two aerobic-type hemoculture broth bottoms of blood specimens from a Rajavithi's patient a 38-year old Thai male, admitted to the neurosurgical ward, where he had been detected positive. Of them, were subcultured on chocolate agar (CA), sheep blood agar (SBA), and MacConkey (MAC) agar. Both CA and SBA have been incubated in 5% CO₂. All agar plates were incubated at 35°C for 24 h. There are bacterial colonies grow on CA, SBA, and MAC. The colony was identified by MALDI-TOF MS with phenotypic characteristics: colony morphology, Gram staining and conventional biochemical profile⁽¹⁵⁾.

Bacterial identification

Identification by MALDI-TOF MS

The colony was identified by the MALDI-TOF MS was done on a Microflex LT instrument (Bruker Daltonics, Bremen, Germany) using the FlexControl 3.4 software (Bruker Daltonics) which of the maldi biotyper 3.1 (Referencelibrary version 4.0.0.1 software, containing 5,627 species). Briefly, the colony was picked, smeared on target, dried in room temperature, and extracted by a formic acid-acetonitrile⁽¹²⁾.

Identification by phenotypic characteristic⁽¹⁵⁾

The colony was identified by Gram staining and conventional biochemical tests, including Kligler's iron agar (KIA), H₂S production, motility, indole, citrate utilization, malonate utilization, urease, lysine decarboxylase, arginine dihydrolase, ornithine decarboxylase, oxidation/fermentation (O/F) of glucose and manitol, NaCl broth (0, 1, 3, 6, 8, 10% NaCl), esculin hydrolysis, nitrate reduction, catalase, oxidase tests.

Antimicrobial susceptibility testing (AST)

AST by disk diffusion method

Both of *L. hongkongensis* isolates were performed by the Kirby-Bauer disk diffusion method. Disks of 14 antimicrobial agents were used as follows: Beta-lactams including Penicillins, ampicillin (AM); Cephalosporins, cefotaxime (CTX), ceftriaxone (CRO) and ceftazidime (CAZ); Carbapenems; doripenem (DOR) and meropenem (MEM), Beta-lactam combination agents, amoxicillin-clavulanate (AMC), piperacillin-sulbactam (TZP), cefoperazone-sulbactam (SCF), refer to the

manufacturer's instructions; Non-beta-lactams including Aminoglycosides; gentamicin (GM), and amikacin (AN); tetracycline (TE); chloramphenicol (C); Folate pathway inhibitors, trimethoprim-sulfamethoxazole (SXT). The results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines for *Enterobacteriaceae*⁽¹⁶⁾.

AST by MICs using the gradient diffusion method E-test

Both of isolates were performed by the minimal inhibitory concentrations (MICs) of 6 antimicrobial agents were used as followed: ceftriaxone (CRO) and ceftazidime (CAZ), imipenem (IPM), meropenem (MEM), ciprofloxacin (CIP), and levofloxacin (LEV). The results of MICs breakpoints were interpreted according to CLSI guidelines for other non-*Enterobacteriaceae*⁽¹⁶⁾.

Results

Using the MALDI-TOF MS, these bacterial colonies were identified that *L. hongkongensis*, with a scores ranging from 2.405-2.437.

The phenotypic characterization of *L. hongkongensis* (LHRJ) strain was determined followed by colony morphology, Gram staining, and biochemical tests. Figure 1 shows the colonies of *L. hongkongensis* grow on CA, SBA, and MAC at 35°C, in ambient condition, a colorless colony 1 mm in a diameter. The colonies are non-hemolysis on SBA, and non-lactose fermenter on MAC. Figure 2 had shown Gram staining of *L. hongkongensis*, a gram-negative, curve-shaped rod. The biochemical tests of *L. hongkongensis* (LHRJ) isolate had shown in Table 1, it was a non-fermentative (K/N, K/K), non-oxidizer (both with glucose




Figure 1. Characterization of *Laribacter hongkongensis* colony on chocolate agar (CA), sheep blood agar (SBA), and MacConkey agar (MAC). The colony is approximately 1 mm in a diameter, non-hemolysis on SBA, and non-lactose fermenter on MAC.




Figure 2. Gram's stain: *Laribacter hongkongensis* is a gram-negative, curved-shaped bacillus.

and manitol). It was tested positive for motility, urease, arginine dihydrolase, oxidase, catalase, and reduces nitrate. It showed growth in 0 and 1% NaCl, but not in 3, 6, 8, and 10% NaCl. It tested negative for citrate and malonate utilization, indole and H₂S production, lysine and ornithine decarboxylase and esculin hydrolysis.

This *L. hongkongensis* (LHRJ) strain was susceptible to amoxicillin-clavulanate (AMC), piperacillin-tazobactam (TZP), cefoperazone-sulbactam (SCF), doripenem (DOR), imipenem (IPM), meropenem (MEM), gentamicin (GM), amikacin (AN), chloramphenicol (C), tetracycline (TE), trimethoprim-sulfamethoxazole (SXT), ciprofloxacin (CIP), and levofloxacin (LEV), but resist to ampicillin (AM), cefotaxime (CTX), ceftriaxone (CRO), and ceftazidime (CAZ).

Discussion

The current methods for accurate identification of *L. hongkongensis* are based on a molecular method and the MALDI-TOF MS. It may be misidentified to other genres and species by using conventional biochemical tests and the automatic machines which have no database of *L. hongkongensis* strains^(1,8,12-14).

The clinical microbiology laboratory technician did not overlook the colonies of *L. hongkongensis*; because of its non-fastidious bacteria, it was easy to grow on CA, SBA (non-hemolysis), and MAC (non-lactose fermenter) at 35°C in ambient air and a colorless colony in 1 mm in diameter.

Table 1. Biochemical reaction or enzyme of *Laribacter hongkongensis* (RJLH strain)

| Biochemical reaction or enzyme | Result |
|--------------------------------|----------------------------|
| Kliger's iron agar (KIA) | K/N, N/N |
| H ₂ S | Negative |
| Motility medium test | Motile |
| Indole | Negative |
| Citrate utilization | Negative |
| Malonate utilization | Negative |
| Urease | Positive |
| Lysine decarboxylase | Negative |
| Arginine dihydrolase | Positive |
| Ornithine decarboxylase | Negative |
| Fermentation/Oxidation (O/F) | |
| - O/F glucose | Negative (Non-oxidizer) |
| - O/F mannitol | Negative (Non-oxidizer) |
| % NaCl | |
| 0% NaCl | Positive |
| 1% NaCl | Positive |
| 3% NaCl | Negative |
| 6% NaCl | Negative |
| 9% NaCl | Negative |
| 10% NaCl | Negative |
| Esculin hydrolysis | Negative |
| Catalase | Positive |
| Oxidase | Positive |
| Nitrate reduction | Positive |

There was misidentification because we do not know *L. hongkongensis*, which is not included in textbook bacterium⁽¹⁵⁾.

The important phenotypic characteristics to differentiate other organisms are the morphology in Gram's stain: a gram-negative, curved-shaped rod; the biochemical tests: non-fermentative bacteria, the urease, motile, and catalase, oxidase and arginine dihydrolase tests are positive. However, suspected identification of bacterium should be confirmed by using molecular methods or MALDI-TOF MS.

For the phenotypic characteristics of *L. hongkongensis* (LHRJ) strain, most of them were similar to those of Yuen KY⁽¹⁾, Ni XP⁽⁷⁾ and Beilfuss HA⁽¹⁴⁾; however, some characteristics were different. The LHRJ isolates were motile, similar to those of Beilfuss HA⁽¹⁴⁾ and Ni XP⁽⁷⁾, which showed up to 5 bipolar tufted flagella, but differ from those of Yuen KY⁽¹⁾. In contrast from the study of Beilfuss HA⁽¹⁴⁾, the isolates deny malonate utilization. The LHRJ strain grew in 0 and 1% NaCl, but did not grow in 3, 6, 8, 10% NaCl which was similar to the strain of Yuen KY⁽¹⁾.

For antimicrobial susceptibility testing (AST), the LHRJ strain was resistant to AM, CTX, CRO, and CAZ, but susceptible to carbapenems (DOR, IPM, and MEM), AMC, aminoglycosides (GM and AN), and fluoroquinolones (CIP and LEV), which was similar to those of Lau SK⁽¹¹⁾ and TengJL⁽⁴⁾. However, the LHRJ strain was susceptible to TZP, which differ from those of Kim DS⁽⁸⁾. Nonetheless, previous

Table 2. Antimicrobial susceptibility of *Laribacter hongkongensis* (LHRJ) strain

| Antimicrobial Class/Subclass | | Antimicrobial agents | | Interpretation | | | |
|------------------------------|--------------------------------|-------------------------------|------------|----------------|------------|----|---|
| | | | | Disk Diffusion | MIC (mg/L) | | |
| Beta-lactams class | Penicillins | Ampicillin | AM | R | | | |
| | Beta-lactam Combination agents | Amoxicillin-clavulate | AMC | S | ND | - | |
| | | Piperacillin-tazabactam | TZP | S | ND | - | |
| | | Cefoperazone-sulbactam | SCF | S | ND | - | |
| | Cephalosporins | Cefotaxime | CTX | R | ND | - | |
| | | Ceftriaxone | CRO | R | >32 | R | |
| | | Ceftazidime | CAZ | R | >256 | R | |
| | Carbapenems | Doripenem | DOR | S | | | |
| | | Imipenem | IPM | ND | 0.047 | S | |
| | | Meropenem | MEM | S | 0.004 | S | |
| | Non-beta-lactams class | Aminoglycosides | Gentamicin | GM | S | ND | - |
| | | | Amikacin | AN | S | ND | - |
| Quinolones | | Ciprofloxacin | CIP | ND | 0.012 | S | |
| | | Levofloxacin | LEV | ND | 0.008 | S | |
| Folate pathway inhibitors | | Trimethoprim-sulfamethoxazole | SXT | S | ND | - | |
| Phenicol | | Chloramphenicol | C | S | ND | - | |
| Tetracyclines | | Tetracycline | TE | S | ND | - | |

S = susceptible; R = resistant; ND = not done

described studies of Yuen KY⁽¹⁾ and Kim DS⁽⁸⁾, the isolates were susceptible to CTX and CAZ.

The report of Wu HK, had presented multidrug resistance (MDR) and resistance genes have been identified in *L. hongkongensis* isolates from Guangzhou, China, including resistant to AM, ampicillin-sulbactam, CTX, CRO, CAZ, CIP, LEV, SXT, TE, and streptomycin, but susceptible to IPM⁽¹⁷⁾. In addition, the study of Lau SK⁽⁹⁾ and Wu HK⁽¹⁷⁾, were reported about tetracycline resistance, from *tetA* plasmid-encoding and *tetG*.

To review this organism, searching the Pubmed by using *Laribacter hongkongensis* and human diseases, and English language, the reports of *L. hongkongensis* found 58 publications with 17 reports caused of human diseases. This case (LHRJ strain) is the first report isolated from Thailand, which was isolated in 2017. All cases found were varied in ages and not significant in children or elders.

Conclusion

This is the first report of *L. hongkongensis* identification in Thailand. The LHRJ strain was isolated from blood of 38-year-old Thai male. The LHRJ isolate was identified by using MALDI-TOF MS method. The phenotypic characteristic of *L. hongkongensis* isolate was described to encourage concern about this organism among microbiology laboratory in Thailand.

The LHRJ stain resists to AM, CTX, CRO and CAZ. However, the antimicrobial susceptibility of *L. hongkongensis* isolates should be tested by MICs method

on each individual isolate, because there had been different antibiotic susceptible patterns among individuals.

What is already known on this topic?

- 1) Usual commercial biochemical tests cannot identify of *L. hongkongensis* correctly.
- 2) MALDI-TOF MS, which has a database of *L. hongkongensis*, can identify the strain correctly.
- 3) Awareness of *L. hongkongensis* should be concerned by using key phenotypic characterization and molecular confirmation method, especially laboratory without MALDI-TOF.
- 4) Antimicrobial susceptibility testing of *L. hongkongensis* should be done, because of individual susceptibility patterns.

What this study adds?

In the future, the correct data of *L. hongkongensis* should be studied, including prevalence, and antimicrobial susceptibility for appropriate treatment and infection control committee (ICC) prevention.

Potential conflicts of interest

The authors declare no conflict of interest.

References

1. Yuen KY, Woo PC, Teng JL, Leung KW, Wong MK, Lau SK. *Laribacter hongkongensis* gen. nov., sp. nov., a novel gram-negative bacterium isolated from a cirrhotic

- patient with bacteremia and empyema. *J Clin Microbiol* 2001;39:4227-32.
2. Woo PC, Lau SK, Teng JL, Que TL, Yung RW, Luk WK, et al. Association of *Laribacter hongkongensis* in community-acquired gastroenteritis with travel and eating fish: a multicentre case-control study. *Lancet* 2004;363:1941-7.
 3. Raja MK, Lulu SS, Ghosh AR. A novel pathogen for gastroenteritis: *Laribacter hongkongensis*. *Indian J Med Microbiol* 2013;31:204.
 4. Teng JL, Woo PC, Ma SS, Sit TH, Ng LT, Hui WT, et al. Ecoepidemiology of *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis. *J Clin Microbiol* 2005;43:919-22.
 5. Lau SK, Lee LC, Fan RY, Teng JL, Tse CW, Woo PC, et al. Isolation of *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis, from Chinese tiger frog. *Int J Food Microbiol* 2009;129:78-82.
 6. Woo PC, Lau SK, Teng JL, Yuen KY. Current status and future directions for *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis and traveller's diarrhoea. *Curr Opin Infect Dis* 2005;18:413-9.
 7. Ni XP, Ren SH, Sun JR, Xiang HQ, Gao Y, Kong QX, et al. *Laribacter hongkongensis* isolated from a patient with community-acquired gastroenteritis in Hangzhou City. *J Clin Microbiol* 2007;45:255-6.
 8. Kim DS, Wi YM, Choi JY, Peck KR, Song JH, Ko KS. Bacteremia caused by *Laribacter hongkongensis* misidentified as *Acinetobacter lwoffii*: report of the first case in Korea. *J Korean Med Sci* 2011;26:679-81.
 9. Lau SK, Ho PL, Li MW, Tsoi HW, Yung RW, Woo PC, et al. Cloning and characterization of a chromosomal class C beta-lactamase and its regulatory gene in *Laribacter hongkongensis*. *Antimicrob Agents Chemother* 2005;49:1957-64.
 10. Lau SK, Wong GK, Li MW, Woo PC, Yuen KY. Distribution and molecular characterization of tetracycline resistance in *Laribacter hongkongensis*. *J Antimicrob Chemother* 2008;61:488-97.
 11. Lau SK, Wong GK, Poon RW, Lee LC, Leung KW, Tse CW, et al. Susceptibility patterns of clinical and fish isolates of *Laribacter hongkongensis*: comparison of the Etest, disc diffusion and broth microdilution methods. *J Antimicrob Chemother* 2009;63:704-8.
 12. Bizzini A, Durussel C, Bille J, Greub G, Prod'homme G. Performance of matrix-assisted laser desorption/ionization-time of flight mass spectrometry for identification of bacterial strains routinely isolated in a clinical microbiology laboratory. *J Clin Microbiol* 2010;48:1549-54.
 13. Tang BS, Lau SK, Teng JL, Chan TM, Chan WS, Wong TY, et al. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry for rapid identification of *Laribacter hongkongensis*. *J Clin Pathol* 2013;66:1081-3.
 14. Beilfuss HA, Quig D, Block MA, Schreckenberger PC. Definitive identification of *Laribacter hongkongensis* acquired in the United States. *J Clin Microbiol* 2015;53:2385-8.
 15. Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, et al. Manual of clinical microbiology. 11th ed. Washington, DC: American Society for Microbiology; 2015.
 16. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 27th ed. CLSI supplement M100. Wayne, PA: CLSI; 2017.
 17. Wu HK, Chen JH, Yang L, Li AR, Su DH, Lin YP, et al. Emergence and genomic analysis of MDR *Laribacter hongkongensis* strain HLGZ1 from Guangzhou, China. *J Antimicrob Chemother* 2018;73:643-7.